Lunesta (Eszopiclone) Dose Adjustments for East Asian Patients
Evidence-based guide to eszopiclone dosing in East Asian populations, covering CYP3A4 pharmacogenomics, body-weight considerations, and clinical monitoring recommendations.
Ethnicity Eszopiclone
9 clinically reviewed articles, written and peer-reviewed by the HealthRX.com Medical Team.
9articles
3topic areas covered
May 27, 2026latest review
Ethnicity Eszopiclone library
Showing 9 of 9 clinical reviews.
Lunesta (Eszopiclone) in Black / African Ancestry Patients: Documented Efficacy Gaps
Evidence review of eszopiclone efficacy, pharmacogenomic variability, and dosing considerations for Black and African ancestry patients, with cited trial data and clinical guidance.
Lunesta (Eszopiclone) in South Asian Patients: Safety Profile Differences
Evidence-based review of how eszopiclone (Lunesta) safety and pharmacogenomics differ in South Asian populations, including CYP3A4 metabolism, dosing considerations, and cardiovascular overlap.
Lunesta (Eszopiclone) Safety Profile Differences in Black and African Ancestry Patients
A clinician-reviewed guide to eszopiclone pharmacokinetics, pharmacogenomics, and safety considerations specific to Black and African ancestry patients, including CYP3A4 variation, G6PD prevalence, hypertension drug interactions, and dosing guidance.
Lunesta East Asian Documented Efficacy Gaps: Pharmacogenomics, Dosing, and What the Data Actually Show
East Asian patients metabolize eszopiclone (Lunesta) faster through CYP2C19 ultrarapid pathways, producing measurable efficacy gaps. Learn what the pharmacogenomic data show, how dosing should be adjusted, and what clinicians need to know before prescribing.
Lunesta East Asian Safety Profile Differences: What Patients and Prescribers Need to Know
East Asian patients metabolize eszopiclone (Lunesta) differently due to CYP2C19 poor-metabolizer rates up to 15%, raising exposure, next-day sedation risk, and dosing considerations. Learn the pharmacogenomic basis, recommended starting doses, and monitoring guidance.
Lunesta Hispanic / Latino Safety Profile Differences: What Patients and Clinicians Need to Know
A clinical deep-dive into eszopiclone (Lunesta) safety, dosing, and pharmacogenomics in Hispanic / Latino patients, including CYP3A4/5 variation, diabetes comorbidity risk, and FDA-label guidance.
Lunesta in Hispanic / Latino Patients: Documented Efficacy Gaps and What Clinicians Need to Know
An evidence-based review of eszopiclone (Lunesta) efficacy differences in Hispanic / Latino patients, covering pharmacogenomics, CYP2C19 variants, diabetes co-morbidity, and dosing considerations.
Lunesta South Asian Documented Efficacy Gaps: What the Pharmacogenomic Data Show
Eszopiclone (Lunesta) may work differently in South Asian patients due to CYP3A4/CYP2C19 variation, body-composition differences, and underrepresentation in key trials. This review covers the pharmacogenomic evidence, dose considerations, and clinical decision points.